Back to top
more

BioCryst Pharmaceuticals (BCRX)

(Real Time Quote from BATS)

$8.10 USD

8.10
504,993

+0.32 (4.11%)

Updated Nov 11, 2024 12:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?

by Zacks Equity Research

Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

    BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall

    by Zacks Equity Research

    Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.

      Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?

      by Zacks Equity Research

      Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

        Implied Volatility Surging for BioCryst (BCRX) Stock Options

        by Zacks Equity Research

        Investors in BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately.

          What's in the Cards for Ecolab (ECL) this Earnings Season?

          by Zacks Equity Research

          Ecolab Inc. (ECL), a leading provider of water, hygiene and energy technologies and services, is expected to report first-quarter 2017 results on May 2.

            Can Cardinal Health (CAH) Bring On a Beat in Q3 Earnings?

            by Zacks Equity Research

            Cardinal Health (CAH), a global player in the healthcare services and products space, is set to report third-quarter fiscal 2017 results on May 1, before the bell.

              Will Baxter International (BAX) Disappoint in Q1 Earnings?

              by Zacks Equity Research

              Baxter International Inc. (BAX) is scheduled to report first-quarter 2017 earnings on Apr 26, before the opening bell.

                Is a Surprise in Store for C.R. Bard (BCR) in Q1 Earnings?

                by Zacks Equity Research

                CR Bard Inc. (BCR) is scheduled to report first-quarter 2017 earnings, after market close on Apr 26.

                  Will Stryker (SYK) Deliver a Beat this Earnings Season?

                  by Zacks Equity Research

                  Stryker Corporation (SYK), a leading player in the medical technology space, is set to report first-quarter 2017 results on Apr 25 after the bell.

                    Teva Launches Authorized Generic of Allergan's Minastrin

                    by Zacks Equity Research

                    Teva Pharmaceutical Industries Ltd. (TEVA) recently launched an authorized generic version of Allergan plc???s (AGN) oral contraceptive, Minastrin 24 Fe1, in the U.S.

                      Jazz Initiates Phase III Study for Narcolepsy Candidate

                      by Zacks Equity Research

                      Jazz Pharmaceuticals plc (JAZZ) recently announced the initiation of patient enrollment in a phase III study evaluating the efficacy and safety of its pipeline candidate, JZP-258, for the potential treatment of adult narcolepsy patients.

                        Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4

                        by Zacks Equity Research

                        Conatus Pharmaceuticals Inc. (CNAT) reported fourth-quarter 2016 loss of 35 cents per share, wider than both the Zacks Consensus Estimate of a loss of 32 cents and the year-ago figure of 30 cents.

                          AstraZeneca's Cancer Drug Lynparza Positive in Phase III

                          by Zacks Equity Research

                          AstraZeneca plc (AZN) announced positive results from phase III SOLO-2 study which support the potential benefit of marketed drug Lynparza (olaparib) as a maintenance therapy in relapsed ovarian cancer.

                            Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up

                            by Zacks Equity Research

                            Arena Pharmaceuticals, Inc. (ARNA) reported earnings of 16 cents per share in the fourth quarter of 2016, as against the year-ago loss of 13 cents and the Zacks Consensus Estimate of a loss of 9 cents.

                              BioCryst Pharmaceuticals (BCRX) Shares March Higher, Can It Continue?

                              by Zacks Equity Research

                              BioCryst Pharmaceuticals, Inc. (BCRX) has been on the move lately as the stock has risen by 46.8% in the past four weeks, and it is currently trading well above its 20-Day SMA

                                Arpita Dutt headshot

                                After Valeant, Here are 5 Drug Stocks Bill Ackman Should Buy Instead

                                by Arpita Dutt

                                With Bill Ackman finally deciding to exit Valeant (VRX), here is a look at 5 Zacks Rank #1 and #2 drug stocks that the billionaire investor could consider buying.

                                  Adamis (ADMP) Shows Strength: Stock Gains 6.7% in Session

                                  by Zacks Equity Research

                                  Adamis Pharmaceuticals Corporation (ADMP) moved big last session, as its shares rose over 6% on the day

                                    Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock?

                                    by Zacks Equity Research

                                    Investors in BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately.

                                      Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock?

                                      by Zacks Equity Research

                                      Investors in shares of BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately.

                                        Can The Uptrend Continue for BioCryst Pharmaceuticals (BCRX)?

                                        by Zacks Equity Research

                                        Investors certainly have to be happy with BioCryst Pharmaceuticals, Inc. (BCRX) and its short term performance.

                                          3 Biotechs Looking Good this Earnings Season

                                          by Zacks Equity Research

                                          A number of biotech companies are seeing improvements in their financial results.